Features of the course and therapeutic strategy of ulcerative colitis in liver transplant recipients

The aim of this review is to assess the proposed mechanisms of pathogenesis underlying the maintenance of UC activity in liver recipients, as well as the efficacy and safety of drugs proposed for the treatment of UC in this group of patients. Materials and methods. A literature review concerning the topic of inflammatory bowel diseases in liver recipients was conducted. Results. Inflammatory bowel diseases (IBD) are often associated with liver diseases such as primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and primary biliary cholangitis (PBC). Up to 80% of patients with PSC have concomitant IBD. Conversely, only 5% of patients with IBD have PSC. The most common IBD variants are ulcerative colitis (UC), which occurs in 50-80% of patients with PSC, and Crohn’s disease (CD), which occurs in 20% of cases of PSC. Patients with PSC and UC have specific clinical features and are classified as a separate IBD phenotype, distinct from patients with UC alone. Liver transplantation (LT) remains the only radical treatment for advanced stages of chronic diffuse liver diseases. After TP, all recipients receive maintenance immunosuppressive therapy (IST). The drugs used for IST lead to a change in the course of UC in this group of patients. According to current clinical guidelines, the drugs.